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In addition to the metal ion, copper-containing amine oxidases possess an organic prosthetic group, the 
nature of which has long been controversial. We show here that in the case of bovine plasma amine 
oxidase, this second prosthetic group is covalently bound pyrroloquinoline quinone (PQQ). Until now the 
coenzyme PQQ has been found in several bacterial dehydrogenases. Thus the finding reported here is the 
first example of a quinoprotein oxidoreductase discovered in a eukaryotic organism. 
Bovine serum amine oxidase Pyrroloquinoline quinone (PQQ Quinoprotein 
Copper-containing amine oxidase Prosthetic group 
1. INTRODUCTION 
Oxidative deamination of amines is catalyzed by 
two groups of enzymes. One is the class of copper- 
containing amine oxidases (e.g., EC 1.4.3.6), in 
which a covalently bound prosthetic group can 
also be detected after removal of copper [l]. It is 
generally accepted that this prosthetic group has a 
carbonyl function since the absorption spectrum of 
the enzyme changes on addition of carbonyl-group 
reagents like hydrazine [2,3]. As the maximum in 
the spectrum of the modified enzyme is similar to 
that of pyridoxal phosphate (PLP)-containing en- 
zymes treated with a hydrazine [4], this observa- 
tion has played a suggestive role in the formation 
of a concept about the nature of the prosthetic 
group. It should be noted, however, that a PLP- 
adduct has never been isolated as such from pure 
enzyme. Furthermore, based on mechanistic 
studies [5,6], it seems unlikely that PLP is involved 
in the catalytic cycle, although the difficulties can 
be circumvented by assuming [7] that copper par- 
ticipates in the redox steps. A quite different pro- 
position, avoiding these difficulties, has been put 
forward [8], namely that a ring-opened flavin 
derivative could be the prosthetic group. However, 
in this respect pyrroloquinoline quinone (PQQ) is 
also a good candidate, showing carbonyl-group 
functionality as well as redox behaviour [9]. As no 
information is yet available on the presence of this 
coenzyme in eukaryotes, we decided to investigate 
the possible occurrence of PQQ in bovine serum 
amine oxidase, a mammalian copper-containing 
amine oxidase. 
2. METHODS 
2.1. Enzyme isolation 
* To whom correspondence should be addressed 
Fresh bovine serum was treated with solid 
(NH&S04 and the fraction precipitating between 
30 and 60% saturation was dissolved in and dialyz- 
ed against 10 mM potassium phosphate (pH 7.0). 
This solution was applied to a DEAE-Sepharose 
column equilibrated with 10 mM potassium 
phosphate (pH 7.0). After washing with this buf- 
fer, the enzyme was eluted with a linear gradient o 
0.5 M potassium phosphate (pH 7.0). Active frac- 
tions were pooled and dialyzed against 10 mM 
potassium phosphate (pH 7.0), containing 0.15 M 
NaCl, 0.1 mM CaC12 and 0.1 mM MnC12. The 
solution was applied to a ConA-Sepharose col- 
umn, equilibrated with the latter buffer. After 
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washing with this buffer, the enzyme was eluted 
with this buffer, containing 0.5 M a-D- 
methylglucoside. Active fractions were dialyzed 
against 10 mM potassium phosphate (pH 7.0) and 
applied to a Procion red-Sepharose column, 
prepared as in [lo]. After washing with 20 mM 
Tris-HCl (pH 7.0) containing 5 mM KCI, the en- 
zyme was eluted with 20 mM Tris-HCI (pH 7.0) 
containing 0.5 M KCl. Active fractions were pooled 
and dialyzed against 70 mM potassium phosphate 
(pH 7.0). 
potassium phosphate (pH 7.0) and the solution 
passed through a Seppak Cl8 cartridge. The car- 
tridge was washed with 1 M HCl, followed by 
H20, and the model compound eluted with 
methanol. 
2.6. Analytical procedures 
2.2. Modification of the enzyme 
‘H-NMR spectroscopy of the model compound 
was performed in (C’H&SO with a Varian SC 300 
spectrometer, operating at 300 MHz, using the 
pulse Fourier-transform mode (max 32 K data 
table of 32 bits) and tetramethylsilane as an inter- 
nal reference. 
Adduct of the prosthetic group in the enzyme 
was obtained by incubating 4.5 ml enzyme (14 mg 
protein) in 70 mM potassium phosphate (pH 7.0) 
with 80 ~1 of 2 mM 2,4_dinitrophenylhydrazine 
(DNP) in 0.1 M HCl at 37°C for 16 h. Excess 
reagent was removed by gel filtration on a 
Sephadex G-25 column in 70 mM potassium 
phosphate, pH 7.0. 
2.3. Proteolysis of modified enzyme 
Modified enzyme (4.5 ml) was denatured 
anaerobically by adding 1 ml of 8 M urea, 0.3 ml 
of 3 M Tris-HCl (pH 8.6), and 10~1 ,&- 
mercaptoethanol. Free SH-groups were blocked by 
adding 200 mg &bromoethylamine. After desalt- 
ing on a Sephadex G-25 column in 10 mM potas- 
sium phosphate (pH 7.5), proteolysis was started 
by adding 0.3 mg cu-chymotrypsin and incubating 
at 37’C for 48 h. The solution was acidified to pH 
3.0 with acetic acid and proteolysis continued by 
adding 0.3 mg pepsin and incubating at 37°C for 
48 h. Thereafter the solution was brought to pH 
7.5, 0.3 mg pronase was added and the incubation 
continued at 37°C for 48 h. 
The HPLC system consisted of a Waters 6000 A 
pump, equipped with a U6K injection block. Gel 
filtration was performed on a Serva SI 200 Polyol 
(5 pm) column and as eluant (1 ml/min) 0.1 M 
potassium phosphate (pH 7.0). Reversed phase 
chromatography of the model compound and the 
adduct was performed with an RCM 100 module 
containing a 10sm Cis RCM cartridge while the 
eluant (1.5 ml/min) consisted of methanol/O.01 M 
potassium phosphate (pH 7.0) (22.5:77.5, v/v). 
The eluates were monitored with a Hewlett- 
Packard 1040 A photodiode-array detector, taking 
absorption spectra of the eluting peaks, upslope, at 
the top, and downslope, to check homogeneity and 
identity. 
2.4. Isolation of the adduct 
After proteolysis of the modified enzyme, the 
solution was brought to pH 5.5, and passed 
through a Seppak Cl8 cartridge. After washing 
with 1 M HCl, followed by H20, the retained ad- 
duct was eluted with methanol/O.01 M potassium 
phosphate (pH 7.0) (22.5:77.5, v/v). 
Conversion of PQQ, adduct or model com- 
pound into fluorescing product was achieved by 
adding 25-~1 samples to 1 ml of 50% (w/w) NaOH 
solution in an ampoule. After evacuation and seal- 
ing, it was kept at 100°C for 45 min. The ampoule 
was opened and the contents diluted lo-fold with 
H20. The solution was acidified to pH 2.0 with a 
concentrated HCI solution and passed through a 
Seppak Cig cartridge. The cartridge was washed 
with Hz0 and the fluorescing compound eluted 
with methanol. Reversed phase chromatography 
of the fluorescing compound was performed as 
above, using methanol/0.4% H3P04 (50: 50, v/v) 
as the eluant. The effluent was monitored with 
fluorescence detection (Waters model 420 AC, h,,, 
= 360 nm, and h,, > 418 nm). 
2.5. Preparation of the model compound 
3. RESULTS 
PQQ (15 mg) and 37 mg DNP in 4 M HCl were 3.1. The model compound 
incubated for several hours at 20°C. After cen- The product obtained by reacting PQQ with 
trifugation, the precipitate was dissolved in 0.1 M DNP was homogeneous as revealed by HPLC 
306 
Volume 170, number 2 FEBS LETTERS May 1984 
> 
Fig. 1. HPLC of the model compound (a) and the adduct 
isolated from the enzyme (b). The system consisted of a 
Waters model 6000 A pump, equipped with U6K 
injection block and an RCM module, containing a 
10,um Cl8 cartridge. The eluant (1.5 ml/min) was 
methanol/O.01 M potassium phosphate (pH 7.0) 
(22.5:77.5, v/v) and was monitored by a Hewlett- 
Packard 1040 A photodiode-array detector. Peaks were 
investigated for homogeneity by taking absorption 
spectra, upslope, at the top, and downslope. 
(fig.1) and had an absorption spectrum as shown 
in fig.2. Product formation easily occurred under 
the strong acid conditions but very slowly at pH 
7.0. ‘H-NMR spectroscopy showed signals at 7.04 
(s, 3-H), 8.37 (s, 8-H), 8.84 (doublet 1.5 Hz, 1 pro- 
ton), 8.44 (multiplet 1.5 Hz and 9.5 Hz, 1 proton) 
and 8.26 ppm (doublet 9.5 Hz, 1 proton). These 
and earlier results [12] indicate that the model 
compound is the monohydrazone of PQQ (most 
probably as the isomer depicted). 
COOH 
3.2. Modified enzyme 
The purified enzyme had a specific activity of 
480 units/mg protein, measured at 25°C as 
reported [ll], and using A&,m,~cm = 17.4 for the 
protein estimation. Specific activity as well as the 
absorption spectrum (fig.3) show that the purity of 
the preparation is comparable to that reported. 
HPLC gel filtration revealed only minor con- 
taminants, having no absorbance above 300 nm. 
Attempts to isolate the prosthetic group as such 
failed as many compounds were found after 
degradation of the enzyme. Since PQQ reacts with 
certain amino acids to yield several products [ 121, 
we therefore tried to derivatize the prosthetic 
group in the enzyme into a stable adduct. 
Bovine serum amine oxidase is inhibited im- 
mediately on addition of phenylhydrazine. This 
has been ascribed to reaction with the organic pro- 
sthetic group as the absorption spectrum in the 
visible region changes dramatically [2,3]. 
However, as we could not prepare a model com- 
pound from PQQ and phenylhydrazine, other 
reagents were tested. Since DNP gave a model 
compound which appeared to be reasonably 
stable, this reagent was tried on the enzyme. 
Although the reaction of enzyme with DNP is 
slow, after incubation under the indicated condi- 
tions the enzyme is completely inhibited. The ab- 
sorption spectrum of the modified enzyme (fig.3) 
Fig.2. Absorption spectra of the model compound 
(- ) and the adduct isolated from the enzyme (- - -). 
Spectra were measured with the photodiode-array 
detector (see fig.1 legend). For comparison, the 
spectrum of the adduct was multiplied by a factor 5. 
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Fig.3. Absorption spectra of bovine serum amine 
oxidase (- --) and after modification with DNP 
(-). Enzyme was incubated with DNP and excess 
reagent removed by gel filtration on a Sephadex G-25 
column. 
is very similar to that of the model compound 
(fig.%) but quite different from that obtained by in- 
cubating PLP with DNP (not shown). 
3.3. Properties of the adduct 
Following the above isolation procedure, adduct 
was obtained showing exactly the same retention 
time (fig. 1) and absorption spectrum (fig.2) as the 
model compound. 
To obtain further evidence for the presence of 
PQQ, we tried to dissociate the adduct into its con- 
stituents. However, as conventional methods to 
dissociate the hydrazone failed and a very sensitive 
method was available for the conversion of PQQ 
into a fluorescing product (unpublished), the latter 
method was tried on the model compound and ad- 
duct. The structure of the fluorescing compound is 
not exactly known at the moment, but the results 
indicate that it is comparable to the products ob- 
tained from phenanthroline-diones under similar 
conditions [ 131. Although the fluorescing com- 
pound is a minor product in the reaction, ex- 
periments under standardized conditions showed 
that the amount of fluorescing compound, as 
measured by HPLC, was proportional to the 
amount of PQQ in the sample. On degradation of 
model compound or adduct, a fluorescing product 
with the same retention time as in the case of PQQ 
was obtained (fig.4). 
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Fig.4. HPLC on a reversed phase column of fluorescing 
product obtained by degradation in NaOH solution of 
PQQ (a) and isolated adduct (b). Degradation and 
chromatography conditions are described in section 2. 
Based on an Mr of 172000 (determined by gra- 
dient polyacrylamide gel electrophoresis) and 
assuming one prosthetic group (or reactive car- 
bony1 group) per enzyme molecule [2,3], a yield of 
2% adduct was calculated. However, as it was 
found that the model compound is relatively 
unstable at pH 3.0, we omitted the pepsin digestion 
step. This resulted in a yield of 6.2% adduct. Fur- 
ther experiments howed that the model compound 
is stable in solutin with cu-chymotrypsin but, unfor- 
tunately, not with pronase. However, as the pro- 
nase proteolysis step appeared to be essential for 
obtaining the adduct, this step could not be omit- 
ted. On incubation of DNP with the proteases, no 
adduct was found. 
4. DISCUSSION 
The model compound and the adduct have iden- 
tical absorption spectra and chromatographic pro- 
perties. Alkaline degradation of these compounds 
produces a fluorescing compound which has iden- 
tical chromatographic properties to that obtained 
from PQQ. This indicates that the enzyme 
preparation contains covalently bound PQQ which 
can be detached by proteolysis. 
A yield of only 6% adduct was obtained. It 
should be stressed, however, that the absorption 
spectra of modified enzyme and model compound 
Volume 170, number 2 FEBS 
are very similar. Based on absorbance measure- 
ments, it appeared that all the adduct is still pre- 
sent before the step with pronase. However, during 
this step a large decrease in the absorbance values 
occurs. Since large losses of the model compound 
were found on incubation with pronase (as re- 
vealed by HPLC), the low yield of isolated adduct 
can be explained from the destructive action of this 
step. As no compound with a different visible ab- 
sorption spectrum was detectable in the modified 
enzyme, it is concluded that the organic prosthetic 
group in bovine serum amine oxidase is covalently 
bound PQQ. 
PQQ has only been found in bacterial ox- 
idoreductases [9]. The fact that it has been detected 
now in this amine oxidase provides a stimulus to 
look for its presence in other mammalian enzymes 
and to investigate the eventual role of PQQ as a 
vitamin. 
Plasma amine oxidase converts spermine and 
spermidine into their corresponding aldehydes. 
These compounds function in the regulation of cell 
division [14,15]. As it is clear now that PQQ is in- 
volved in these conversions, PQQ-directed in- 
hibitors, important for chemotherapy [16], might 
be designed. Furthermore, if it appears that other 
copper-containing amine oxidases also contain 
PQQ, these specific inhibitors could clarify the 
physiological role of these enzymes. 
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